O'Hare affected by United's latest computer glitch









United Airlines experienced more computer problems Friday, causing systems to slow down.

"We have been experiencing short-term, intermittent Internet connectivity issues, causing some systems to run more slowly than normal," United spokesman Rahsaan Johnson said.

However, the airline is continuing to operate flights and "take care of customers," he said, adding that interruptions last for about five minutes.

The problem is only at some locations, including Chicago O'Hare International Airport, he said.

The glitch has not harmed the airline's on-time performance, which was running at 91.5 percent for United Airlines flights and about 85 percent for United Express flights, he said. Those rates are higher than normal for United, which has been running closer to 80 percent on time.

Computer problems have plagued the airline this year, starting in March when it switched to a new reservations system. During the summer its operations were especially poor, with rampant flight delays and cancellations.

gkarp@tribune.com

Read More..

Crowdfunding websites clamor for clearer regulation












LONDON (Reuters) – A new breed of internet-based financiers are calling for action to end regulatory uncertainty they say is preventing them from getting money to the small and medium-sized businesses that need it.


The so-called crowdfunding sector raises cash from members of the public to fund lending and investment. Regulators, however, have proved resistant to pleas for adjustments to rules that are tailored to more traditional markets.












“Operators of these platforms find it difficult to launch and flourish because existing EU and UK regulation does not fit the new models,” operators within the sector said in an open letter to EU and UK policymakers on Friday.


The plea coincides with a summit to discuss proposals for regulating a market that has developed in reaction to reduced bank lending to small and medium-sized enterprises because of tougher capital rules and greater regulatory scrutiny.


A host of alternative financing models have cropped up online, many allowing individuals to lend to, or invest in, companies with sums from as little as 10 pounds ($ 16). Massolution, a research and advisory firm specializing in the sector, says that 1.2 billion euros ($ 1.6 billion) was raised globally from crowdfunding last year.


Though some crowdfunding websites have tried to fit their operations within the existing regulatory framework, most remain largely outside it.


Part of the problem in drawing up appropriate regulation is the wide range of activities involved. Some offer debt, some equity, while others seek donations for charity or funding for creative projects in return for some non-financial reward.


With little or no expected returns from the latter, the main regulatory focus would be on equity crowdfunding and peer-to-peer lending.


As well as making sure that individuals are aware of the inherent risk involved with putting money in start-ups, the industry wants to avoid the risk of scams by ensuring that platforms vet businesses adequately.


LOST IN THE CROWD


Britain’s Financial Services Authority (FSA) warned in August that inexperienced investors should be aware of the risks in crowdfunding websites. A few days later United States securities regulators put crowdfunding at the top of their annual investment scams list.


Views differ about how to tackle these risks without stifling an increasingly important source of funding, and the matter is complicated by the varying rules already in place in different countries across Europe.


Measures taken by Seedrs, the only crowdfunding website to have received FSA approval, include requiring investors to pass a test to show that they understand the risks.


“It is hard to come up with a whole securities regulation; sometimes it does have to be a bit incremental and adaptive,” Seedrs founder Jeff Lynn said. “There is no question at all this is going to be a space that will continue to move.”


Some would like the operation of such platforms to be a distinct regulated activity, but others argue for smaller steps, such as a cap on the sums that people can invest or lend.


The British government, keen to improve the flow of finance to small businesses to boost the sluggish economy, has set up a working group to look at all aspects of policy on such sites.


The FSA said that it considers authorization of crowdfunding schemes case by case. The European Commission, meanwhile, is considered as so far having had a largely observational role.


Though the introduction of a separate regulated activity could still be some way off, the co-founder of peer-to-peer site Zopa, Simon Deane-Johns, believes that increased engagement with governments and regulators shows that things are moving in the right direction.


“Over the next year or two it should become progressively easier to set up a platform,” he said, “possibly through a combination of the FSA understanding more readily where things fit within the current regime and balancing that with some self-regulation.”


(Editing by Alexander Smith and David Goodman)


Internet News Headlines – Yahoo! News


Read More..

Preckwinkle rips Emanuel, McCarthy's handling of violence









Cook County Board President Toni Preckwinkle today publicly blasted Mayor Rahm Emanuel’s crime-fighting strategy and the quality of the public schools he controls, then quickly walked back the remarks.

The Democratic leader said her criticism was targeted at society as a whole and not the mayor personally, much as she did last summer when she harshly criticized former President Ronald Reagan for his role in the war on drugs.

The comments about Emanuel came during a question-and-answer session during a luncheon at the Union League Club. Preckwinkle was asked how to address Chicago violence.

“Clearly, this mayor and this police chief have decided the way in which they are going to deal with the terrible violence that faces our community is just arrest everybody,” Preckwinkle said. “I don’t think in the long term that’s going to be successful.

“We’re going to have to figure out how to have interventions that are more comprehensive than just police interventions in the communities where we have the highest rates of crime. And they’re almost all in African-American and Latino communities.”

Homicides and shootings in Chicago have attracted national attention this year following a spike in the city’s murder rate and brazen incidents such as the shooting of a young man at a funeral for a gang member.

Preckwinkle said much of the problem results from a school system that has a low high school graduation rate.

“We have contented ourselves with a miserable education system that has failed many of our children,” Preckwinkle said, saying more after-school enrichment and job-training programs are needed. “I’m talking about the kids who don’t graduate, let alone the kids who graduate don’t get a very good education, even with a high school diploma.”

Emanuel aides responded with restraint, saying the mayor is taking many of the actions Preckwinkle said were needed, even as he maintained a tough stance on crime.


“Mayor Emanuel strenuously agrees that a holistic approach is necessary to successfully address crime,” Emanuel spokeswoman Sarah Hamilton said in a statement. “His multi-part strategy ranges from improving early childhood education, providing a longer school day and creating re-engagement centers for youth, to delivering wrap-around services, revitalizing the community policing program and working to prevent retaliatory actions by gangs.


“All of these work in tandem, but let's make no mistake, criminals deserve to be arrested,” the statement read.

At a news conference after her speech and question session, Preckwinkle said her criticism of schools wasn’t aimed at Emanuel, who as mayor appoints the Chicago Public Schools board and picks the system’s CEO.

“This was a critique of all of us, it wasn’t aimed at the mayor,” said Preckwinkle, a former CPS high school history teacher.

Preckwinkle also acknowledged that Emanuel is putting more city money into early childhood education, after-school programs and youth job programs — in part through programs coordinated with the county.

Her point, she said, was that education over the long run will do more to quell violence than arresting people and locking them up.

“You know unfortunately we live in a country in which we are much more willing to spend money on keeping people in prison than we are on educating them in our public schools,” she said. “And that’s disgraceful. It reflects badly on all of us.”

She added, “I don’t think we are going to arrest our way out of our violence problems.”

Mayor Emanuel's aides said they just learned of the remarks and are preparing a response.

Preckwinkle is a liberal who has been consistently critical of a justice system that locks up African-American and Latino men in far greater numbers than their white counterparts, particularly for drug crimes when studies show drugs are used in equal numbers across ethnic and racial boundaries

It wasn’t the first time that, while speaking without a script, she made comments that ruffled some feathers.

In August, she said former President Ronald Reagan deserved “a special place in hell” for his role in the War on Drugs, later saying she regretted the “inflammatory” remark.

hdardick@tribune.com

Twitter @ReporterHal



Read More..

Actor Stephen Baldwin charged in NY tax case












WHITE PLAINS, N.Y. (AP) — Actor Stephen Baldwin was charged Thursday with failing to pay New York state taxes for three years, amassing a $ 350,000 debt.


Rockland County District Attorney Thomas Zugibe said Baldwin, of Upper Grandview, skipped his taxes in 2008, 2009 and 2010.












The youngest of the four acting Baldwin brothers pleaded not guilty at an arraignment and was freed without bail. His lawyer, Russell Yankwitt, said Baldwin should not have been charged.


“Mr. Baldwin did not commit any crimes, and he’s working with the district attorney‘s office and the New York State Tax Department to resolve any differences,” Yankwitt said.


The district attorney said Baldwin could face up to four years in prison if convicted. The actor is due back in court on Feb. 5.


Zugibe said Baldwin owes more than $ 350,000 in tax and penalties.


“We cannot afford to allow wealthy residents to break the law by cheating on their taxes,” the district attorney said. “The defendant’s repetitive failure to file returns and pay taxes over a period of several years contributes to the sweeping cutbacks and closures in local government and in our schools.”


Thomas Mattox, the state tax commissioner, said, “It is rare and unfortunate for a personal income tax case to require such strong enforcement measures.”


Baldwin, 46, starred in 1995′s “The Usual Suspects” and appeared in 1989′s “Born on the Fourth of July.” He is scheduled to appear in March on NBC’s “The Celebrity Apprentice.”


His brothers Alec, William and Daniel are also actors.


A bankruptcy filing in 2009 said Stephen Baldwin owed $ 1.2 million on two mortgages, $ 1 million in taxes and $ 70,000 on credit cards.


In October, Baldwin pleaded guilty in Manhattan to unlicensed driving and was ordered to pay a $ 75 fine. Earlier this year, he lost a $ 17 million civil case in New Orleans after claiming that actor Kevin Costner and a business partner duped him in a deal related to the cleanup of the 2010 Gulf of Mexico oil spill. The actors and others had formed a company that marketed devices that separate oil from water.


Baldwin co-hosts a radio show with conservative talk figure Kevin McCullough.


Entertainment News Headlines – Yahoo! News


Read More..

Extended Use of Breast Cancer Drug Suggested


The widely prescribed drug tamoxifen already plays a major role in reducing the risk of death from breast cancer. But a new study suggests that women should be taking the drug for twice as long as is now customary, a finding that could upend the standard that has been in place for about 15 years.


In the study, patients who continued taking tamoxifen for 10 years were less likely to have the cancer come back or to die from the disease than women who took the drug for only five years, the current standard of care.


“Certainly, the advice to stop in five years should not stand,” said Prof. Richard Peto, a medical statistician at Oxford University and senior author of the study, which was published in The Lancet on Wednesday and presented at the San Antonio Breast Cancer Symposium.


Breast cancer specialists not involved in the study said the results could have the biggest impact on premenopausal women, who account for a fifth to a quarter of new breast cancer cases. Postmenopausal women tend to take different drugs, but some experts said the results suggest that those drugs might be taken for a longer duration as well.


“We’ve been waiting for this result,” said Dr. Robert W. Carlson, a professor of medicine at Stanford University. “I think it is especially practice-changing in premenopausal women because the results do favor a 10-year regimen.”


Dr. Eric P. Winer, chief of women’s cancers at the Dana-Farber Cancer Institute in Boston, said that even women who completed their five years of tamoxifen months or years ago might consider starting on the drug again.


Tamoxifen blocks the effect of the hormone estrogen, which fuels tumor growth in estrogen receptor-positive cancers that account for about 65 percent of cases in premenopausal women. Some small studies in the 1990s suggested that there was no benefit to using tamoxifen longer than five years, so that has been the standard.


About 227,000 cases of breast cancer are diagnosed each year in the United States, and an estimated 30,000 of them are in premenopausal women with estrogen receptor-positive cancer and prime candidates for tamoxifen. But postmenopausal women also take tamoxifen if they cannot tolerate the alternative drugs, known as aromatase inhibitors.


The new study, known as Atlas, included nearly 7,000 women with ER-positive disease who had completed five years of tamoxifen. They came from about three dozen countries. Half were chosen at random to take the drug another five years, while the others were told to stop.


In the group assigned to take tamoxifen for 10 years, 21.4 percent had a recurrence of breast cancer in the ensuing 10 years, meaning the period 5 to 14 years after their diagnoses. The recurrence rate for those who took only five years of tamoxifen was 25.1 percent.


About 12.2 percent of those in the 10-year treatment group died from breast cancer, compared with 15 percent for those in the control group.


There was virtually no difference in death and recurrence between the two groups during the five years of extra tamoxifen. The difference came in later years, suggesting that tamoxifen has a carry-over effect that lasts long after women stop taking it.


Whether these differences are big enough to cause women to take the drug for twice as long remains to be seen.


“The treatment effect is real, but it’s modest,” said Dr. Paul E. Goss, director of breast cancer research at the Massachusetts General Hospital.


Tamoxifen has side effects, including endometrial cancer, blood clots and hot flashes, which cause many women to stop taking the drug. In the Atlas trial, it appears that roughly 40 percent of the patients assigned to take tamoxifen for the additional five years stopped prematurely.


Some 3.1 percent of those taking the extra five years of tamoxifen got endometrial cancer versus 1.6 percent in the control group. However, only 0.6 percent of those in the longer treatment group died from endometrial cancer or pulmonary blood clots, compared with 0.4 percent in the control group.


“Over all, the benefits of extended tamoxifen seemed to outweigh the risks substantially,” Trevor J. Powles of the Cancer Center London, said in a commentary published by The Lancet.


Dr. Judy E. Garber, director of the Center for Cancer Genetics and Prevention at Dana-Farber, said many women have a love-hate relationship with hormone therapies.


“They don’t feel well on them, but it’s their safety net,” said Dr. Garber, who added that the news would be welcomed by many patients who would like to stay on the drug. “I have patients who agonize about this, people who are coming to the end of their tamoxifen.”


Emily Behrend, who is a few months from finishing her five years on tamoxifen, said she would definitely consider another five years. “If it can keep the cancer away, I’m all for it,” said Ms. Behrend, 39, a single mother in Tomball, Tex. She is taking the antidepressant Effexor to help control the night sweats and hot flashes caused by tamoxifen.


Cost is not considered a huge barrier to taking tamoxifen longer because the drug can be obtained for less than $200 a year.


The results, while answering one question, raise many new ones, including whether even more than 10 years of treatment would be better still.


Perhaps the most important question is what the results mean for postmenopausal women. Even many women who are premenopausal at the time of diagnosis will pass through menopause by the time they finish their first five years of tamoxifen, or will have been pushed into menopause by chemotherapy.


Postmenopausal patients tend to take aromatase inhibitors like anastrozole or letrozole, which are more effective than tamoxifen at preventing breast cancer recurrence, though they do not work for premenopausal women.


Mr. Peto said he thought the results of the Atlas study would “apply to endocrine therapy in general,” meaning that 10 years of an aromatase inhibitor would be better than five years. Other doctors were not so sure.


The Atlas study was paid for by various organizations including the United States Army, the British government and AstraZeneca, which makes the brand-name version of tamoxifen.


Read More..

Macy's to stay open 48 hours on weekend before Christmas













Macy's holiday hours


Katherine Ross hangs ornaments on the 45-foot Great Tree installed in the Walnut Room at Macy's On State Street last month.
(Jose M. Osorio/Tribune / December 6, 2012)





















































Last month for retailers, it was all about post-Turkey spending sprees.

In December, at least one retailer is upping the ante by offering an all-night, last minute shopping marathons.

Macy's announced Thursday that it would open all of its stores for 48-hours straight, giving last-minute shoppers wiggle room to buy gifts the weekend before Christmas.

The extended hours for the New York-based retailer will begin at 7 a.m. on Friday, December 21 and run through 7 a.m. on Sunday, Dec. 23.

At 23 additional locations including Woodfield Mall and Oakbrook Center, Macy's will re-open at 8 a.m on Sunday, Dec. 23 and remain open through the close of business on Christmas Eve. And at 34 locations in California, Nevada and New Jersey, Macy's stores will stay open through 2 a.m. on Monday, December 24.

Macy's experimented with the 48-hour retail marathon in certain test markets last year and found that enough consumers took advantage of the extended hours to warrant rolling out the program to their entire fleet this holiday season, according to spokeswoman Lauren Rapisand.

Many of the shoppers were parents who used the late night hours to shop without children and people who worked late shifts who could get their shopping done during their breaks, according to Rapisand. "We found there were a lot of folks who appreciated the extended hours," she said. "The response was so good in test markets last year that we decided it would be a benefit to all of our stores."

crshropshire@tribune.com

Twitter: @corilyns




Read More..

Windows 8: A ‘Christmas gift for someone you hate’












Microsoft (MSFT) is no stranger to criticism these days, and the company’s new Windows 8 platform is once again the target of a scathing review from a high-profile user. Well-known Internet entrepreneur and MIT professor Philip Greenspun handed Windows 8 one of its most damning reviews yet earlier this week, calling the new operating system a “Christmas gift for someone you hate.” Greenspun panned almost every aspect of Microsoft’s new software, noting that Microsoft had four years to study Android and more than five to examine iOS, but still couldn’t build a usable tablet experience.


“The only device that I can remember being as confused by is the BlackBerry PlayBook,” Greenspun wrote on his blog after using Windows 8 on a Dell (DELL) XPS One All-in-One desktop PC. The acclaimed computer scientist noted that Microsoft omitted all of the best features from the most popular touch-focused platforms and instead created a user interface he describes as a “dog’s breakfast.”












“Suppose that you are an expert user of Windows NT/XP/Vista/7, an expert user of an iPad, and an expert user of an Android phone… you will have no idea how to use Windows 8,” Greenspun wrote.


He continued, “Some functions, such as ‘start an application’ or ‘restart the computer’ are available only from the tablet interface. Conversely, when one is comfortably ensconced in a touch/tablet application, an additional click will fire up a Web browser, thereby causing the tablet to disappear in favor of the desktop. Many of the ‘apps’ that show up on the ‘all apps’ menu at the bottom of the screen (accessible only if you swipe down from the top of the screen) dump you right into the desktop on the first click.”


The only praise Greenspun offered was that “some of the supplied apps are wonderful,” pointing to Microsoft’s Bing Finance application as an example.


Get more from BGR.com: Follow us on Twitter, Facebook


Wireless News Headlines – Yahoo! News


Read More..

Jazz icon Dave Brubeck dead








Dave Brubeck changed the sound of jazz in profound ways, unexpectedly becoming something of a pop star in the process.


Starting in the mid-1950s, in fact, he emerged as a symbol of jazz in America, and well beyond, gracing the cover of Time magazine in 1954 and selling more than a million copies of “Take Five” in 1960. To this day, the puckishly syncopated tune remains one of the most recognizable in jazz, though Brubeck didn’t write it – his alto saxophonist, Paul Desmond, did.


Beneath the popular acclaim stood a brilliant, uncompromising composer-pianist who challenged conventional jazz techniques, brought the music to American college campuses and helped break down racial barriers through a music uniquely suited to that task.






Brubeck was en route to an appointment with his cardiologist when he was stricken Wednesday morning, said his longtime manager-producer-conductor, Russell Gloyd. The pianist died of heart failure at Norwalk Hospital, in Norwalk, Conn., near his home in Wilton, Conn.


Brubeck was anticipating a birthday concert Thursday, when he would have turned 92. The performance will go on, but in the form of a tribute, in Waterbury, Conn.


"Dave Brubeck was one of the giants in the music – he changed the way people listened to the music,” said David Baker, distinguished professor of music at Indiana University and a friend of the Brubeck family.


"He could swing in any time signature – it seemed like forward motion was born in his blood,” said pianist Ramsey Lewis, who played four-hand piano with Brubeck at the Ravinia Festival in Highland Park in 2010. Though the Ravinia Festival does not release attendance figures, a huge audience turned out for that concert, a celebration of Lewis’ 75th birthday.


"Playing with Dave at Ravinia was one of the most exciting moments in my life,” added Lewis.


Brubeck’s last performance in the Chicago area was a 2011 Father’s Day show at Ravinia, where the 90-year-old pianist shared the stage with four sons: pianist Darius, trombonist Chris, cellist Matt and drummer Dan. The elder Brubeck also consistently drew large audiences to Symphony Center, where he last played in 2009.


"Dave Brubeck was one of few jazz headliners who was guaranteed to bring in a large crowd,” said Nick Pullia, Ravinia Festival communications director.


Though widely beloved as an elder statesman in jazz during recent decades, Brubeck’s initial burst of immense popularity, more than half a century ago, caused a backlash. When “Take Five” made him a household name, some critics and deejays accused him of selling out, he said in a 1990 Tribune interview.


"But I had a lot of fun with them,” recalled Brubeck. “One of the most internationally known disc jockeys accused me, right on the air, of going commercial.


"So I said to him, on the air: ‘OK, let’s play the (‘Take Five’) record, and you follow along and count it,’” said Brubeck, referring to its underlying rhythmic pattern, which defied the two-, three- and four-beats-to-the-bar techniques of the day.


"And there was this huge blank – he didn’t say anything.


"So I said, ‘Well, why don’t you do it?’


"And he just didn’t answer.


"At that time, hardly any musicians could play ‘Take Five.’ Now a grammar school kid can play it.


"But those were breakthroughs.”


Brubeck ventured even further afield in another piece that, to his surprise, became a popular hit, his “Blue Rondo a la Turk.” Its lush harmonies sounded exotic in the late ’50s, while its switches between offbeat rhythms and bona fide swing were like nothing yet encountered in American music.


For “Blue Rondo,” Brubeck drew inspiration from a characteristically unlikely source: “I heard street musicians playing in Istanbul,” he said in the 2010 documentary film “In His Own Sweet Way.” By transforming Eastern harmonies and regional rhythms through jazz, Brubeck hit upon an alluring sound and a signature hit.






Read More..

Brazilian architect Oscar Niemeyer dies, aged 104












RIO DE JANEIRO (Reuters) – Oscar Niemeyer, a towering patriarch of modern architecture who shaped the look of modern Brazil and whose inventive, curved designs left their mark on cities worldwide, died late on Wednesday. He was 104.


Niemeyer had been battling kidney ailments and pneumonia for nearly a month in a Rio de Janeiro hospital. His death was confirmed by a hospital spokesperson.












Starting in the 1930s, Niemeyer’s career spanned nine decades. His distinctive glass and white-concrete buildings include such landmarks as the United Nations Secretariat in New York, the Communist Party headquarters in Paris and the Roman Catholic Cathedral in Brasilia.


He won the 1988 Pritzker Architecture Prize, considered the “Nobel Prize of Architecture” for the Brasilia cathedral. Its “Crown of Thorns” cupola fills the church with light and a sense of soaring grandeur despite the fact that most of the building is underground.


It was one of dozens of public structures he designed for Brazil’s made-to-order capital, a city that helped define “space-age” style.


After flying over Niemeyer’s pod-like Congress, futuristic presidential palace and modular ministries in 1961, Yuri Gagarin, the Russian cosmonaut and first man in space, said “the impression was like arriving on another planet.”


In his home city of Rio de Janeiro, Niemeyer’s many projects include the “Sambadrome” stadium for Carnival parades. Perched across the bay from Rio is the “flying saucer” he designed for the Niteroi Museum of Contemporary Art.


The collection of government buildings in Brasilia, though, remain his most monumental and enduring achievement. Built from scratch in a wild and nearly uninhabited part of Brazil’s remote central plateau in just four years, it opened in 1960.


While the airplane-shaped city was planned and laid out by Niemeyer’s friend Lucio Costa, Niemeyer designed nearly every important government building in the city.


BECAME NATIONAL ICON


An ardent communist who continued working from his Copacabana beach penthouse apartment in Rio until days before his death, Niemeyer became a national icon ranking alongside Bossa Nova pioneer Tom Jobim and soccer legend Pelé.


His architecture, though, regularly trumped his politics.


Georges Pompidou, a right-wing Gaullist former French president, said Niemeyer’s design for the Communist Party of France headquarters in Paris “was the only good thing those commies ever did,” according to Niemeyer’s memoirs.


Prada, the fashion company known for providing expensive bags and wallets, thought the Communist Party building in Paris so cool it rented it for a fashion show.


Even the 1964-1985 Brazilian military government that forced Niemeyer into exile in the 1960s eventually found his buildings congenial to their dreams of making Brazil “the country of the future.”


His work is celebrated for innovative use of light and space, experimentation with reinforced concrete for aesthetic value and his self-described “architectural invention” style that produced buildings resembling abstract sculpture.


Initially influenced by the angular modernism of French-Swiss architect Le Cobusier, who worked with Niemeyer and Costa on a visit to Brazil in the 1930s, his style evolved toward rounded buildings that he said were inspired by the curves of Rio’s sunbathing women as well as beaches and verdant hills.


“That is the architecture I do, looking for new, different forms. Surprise is key in all art,” Niemeyer told Reuters in an interview in 2006. “The artistic capability of reinforced concrete is so fantastic – that is the way to go.”


Responding to criticism that his work was impractical and overly artistic, Niemeyer dismissed the idea that buildings’ design should reflect their function as a “ridiculous and irritating” architectural dogma.


“Whatever you think of his buildings, Niemeyer has stamped on the world a Brazilian style of architecture,” Dennis Sharp, a British architect and author of The Illustrated Encyclopedia of Architects and Architecture, once said of Niemeyer.


LIFELONG COMMUNIST


Niemeyer’s legacy is heavily associated with his communist views. He was a close friend of Cuba’s revolutionary leader Fidel Castro and an enemy of Brazil’s 21-year military dictatorship.


“There are only two communists left in the world, Niemeyer and myself,” Castro once joked.


Niemeyer remained politically active after returning to Brazil, taking up the cause of a militant and sometimes violent movement of landless peasants. He said in 2010 that he was a great admirer of Luiz Inacio Lula da Silva, the former labor leader who was Brazil’s president from 2003 to 2010.


Niemeyer once built a house in a Rio slum for his former driver and gave apartments and offices as presents to others.


Despite his egalitarian views, Niemeyer had no illusions that his buildings were helping to improve social justice.


Far from the model city Niemeyer had envisioned, Brasilia today is in many ways the epitome of inequality. Planned for 500,000 people, the city is now home to more than 2.5 million and VIPs keep to themselves in fenced-in villas while the poor live in distant satellite towns.


“It seemed like a new era was coming, but Brazil is the same crap – a country of the very poor and the very rich,” he said in another Reuters interview in 2001.


In a 2010 interview in his office, he was quick to blame Costa for things many dislike about Brasilia, such as its rigid ordering into homogenous “hotel,” “government,” “residential” and even “mansion” and “media” districts that can make finding a newspaper or groceries a chore.


“I just did the buildings,” he said. “All that other stuff was Costa.”


Despite Niemeyer’s atheism, one of his first significant early works was a church built in homage to St. Francis, part of a complex of modern buildings in Belo Horizonte, Brazil.


That work won the confidence of the city’s mayor Juscelino Kubitschek. When he became president, he tapped Niemeyer to help realize the dream of opening up Brazil’s interior by moving the capital from coastal Rio to the empty plains of central Brazil.


Despite years of bohemian living, Niemeyer remained married for 76 years to Annita Baldo, his first wife. He married his second wife, long-time aide Vera Lucia Cabreira, in 2006 at the age of 99. She survives him, as do four grandchildren.


Niemeyer’s only daughter, an architect, designer and gallery owner, Anna Maria, died on June 6 at the age of 82.


(Additional reporting by Brian Ellsworth; Editing by Todd Benson and Kieran Murray)


Celebrity News Headlines – Yahoo! News


Read More..

Extended Use of Breast Cancer Drug Suggested


The widely prescribed drug tamoxifen already plays a major role in reducing the risk of death from breast cancer. But a new study suggests that women should be taking the drug for twice as long as is now customary, a finding that could upend the standard that has been in place for about 15 years.


In the study, patients who continued taking tamoxifen for 10 years were less likely to have the cancer come back or to die from the disease than women who took the drug for only five years, the current standard of care.


“Certainly, the advice to stop in five years should not stand,” said Prof. Richard Peto, a medical statistician at Oxford University and senior author of the study, which was published in The Lancet on Wednesday and presented at the San Antonio Breast Cancer Symposium.


Breast cancer specialists not involved in the study said the results could have the biggest impact on premenopausal women, who account for a fifth to a quarter of new breast cancer cases. Postmenopausal women tend to take different drugs, but some experts said the results suggest that those drugs might be taken for a longer duration as well.


“We’ve been waiting for this result,” said Dr. Robert W. Carlson, a professor of medicine at Stanford University. “I think it is especially practice-changing in premenopausal women because the results do favor a 10-year regimen.”


Dr. Eric P. Winer, chief of women’s cancers at the Dana-Farber Cancer Institute in Boston, said that even women who completed their five years of tamoxifen months or years ago might consider starting on the drug again.


Tamoxifen blocks the effect of the hormone estrogen, which fuels tumor growth in estrogen receptor-positive cancers that account for about 65 percent of cases in premenopausal women. Some small studies in the 1990s suggested that there was no benefit to using tamoxifen longer than five years, so that has been the standard.


About 227,000 cases of breast cancer are diagnosed each year in the United States, and an estimated 30,000 of them are in premenopausal women with estrogen receptor-positive cancer and prime candidates for tamoxifen. But postmenopausal women also take tamoxifen if they cannot tolerate the alternative drugs, known as aromatase inhibitors.


The new study, known as Atlas, included nearly 7,000 women with ER-positive disease who had completed five years of tamoxifen. They came from about three dozen countries. Half were chosen at random to take the drug another five years, while the others were told to stop.


In the group assigned to take tamoxifen for 10 years, 21.4 percent had a recurrence of breast cancer in the ensuing 10 years, meaning the period 5 to 14 years after their diagnoses. The recurrence rate for those who took only five years of tamoxifen was 25.1 percent.


About 12.2 percent of those in the 10-year treatment group died from breast cancer, compared with 15 percent for those in the control group.


There was virtually no difference in death and recurrence between the two groups during the five years of extra tamoxifen. The difference came in later years, suggesting that tamoxifen has a carry-over effect that lasts long after women stop taking it.


Whether these differences are big enough to cause women to take the drug for twice as long remains to be seen.


“The treatment effect is real, but it’s modest,” said Dr. Paul E. Goss, director of breast cancer research at the Massachusetts General Hospital.


Tamoxifen has side effects, including endometrial cancer, blood clots and hot flashes, which cause many women to stop taking the drug. In the Atlas trial, it appears that roughly 40 percent of the patients assigned to take tamoxifen for the additional five years stopped prematurely.


Some 3.1 percent of those taking the extra five years of tamoxifen got endometrial cancer versus 1.6 percent in the control group. However, only 0.6 percent of those in the longer treatment group died from endometrial cancer or pulmonary blood clots, compared with 0.4 percent in the control group.


“Over all, the benefits of extended tamoxifen seemed to outweigh the risks substantially,” Trevor J. Powles of the Cancer Center London, said in a commentary published by The Lancet.


Dr. Judy E. Garber, director of the Center for Cancer Genetics and Prevention at Dana-Farber, said many women have a love-hate relationship with hormone therapies.


“They don’t feel well on them, but it’s their safety net,” said Dr. Garber, who added that the news would be welcomed by many patients who would like to stay on the drug. “I have patients who agonize about this, people who are coming to the end of their tamoxifen.”


Emily Behrend, who is a few months from finishing her five years on tamoxifen, said she would definitely consider another five years. “If it can keep the cancer away, I’m all for it,” said Ms. Behrend, 39, a single mother in Tomball, Tex. She is taking the antidepressant Effexor to help control the night sweats and hot flashes caused by tamoxifen.


Cost is not considered a huge barrier to taking tamoxifen longer because the drug can be obtained for less than $200 a year.


The results, while answering one question, raise many new ones, including whether even more than 10 years of treatment would be better still.


Perhaps the most important question is what the results mean for postmenopausal women. Even many women who are premenopausal at the time of diagnosis will pass through menopause by the time they finish their first five years of tamoxifen, or will have been pushed into menopause by chemotherapy.


Postmenopausal patients tend to take aromatase inhibitors like anastrozole or letrozole, which are more effective than tamoxifen at preventing breast cancer recurrence, though they do not work for premenopausal women.


Mr. Peto said he thought the results of the Atlas study would “apply to endocrine therapy in general,” meaning that 10 years of an aromatase inhibitor would be better than five years. Other doctors were not so sure.


The Atlas study was paid for by various organizations including the United States Army, the British government and AstraZeneca, which makes the brand-name version of tamoxifen.


Read More..